广东伊康纳斯生物医药科技股份有限公司

Econas Biopharmaceutical is a clinical-stage biotechnology company based in Foshan, China, specializing in the development of innovative small molecule drugs and targeted protein degradation therapies. The company leverages its proprietary PROTAC (Proteolysis Targeting Chimera) platform to address unmet medical needs in oncology and metabolic diseases. Its lead candidate, ECN19, is an orally bioavailable androgen receptor degrader currently undergoing clinical evaluation for the treatment of metastatic castration-resistant prostate cancer. Econas aims to transform patient care through the discovery of highly selective and potent degraders for traditionally "undruggable" targets. The company's pipeline also includes degraders targeting the estrogen receptor and Bruton tyrosine kinase for various cancers. By combining deep expertise in medicinal chemistry and protein degradation, Econas is positioned as a leader in the next generation of precision medicine in China.